More importantly, UFMylation has also been involved in the tumor immune evasion via UFMylation of immune checkpoint proteins PD-1/PD-L1 [22–24], which indicated an potential role of UFMylation in the chemotherapy and immunotherapy of GC, and may be potential novel therapeutic targets of GC. This evidence concerns the gene CD274 and neoplasm.